These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 18928745

  • 1. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
    Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Maté J.
    Gastroenterol Hepatol; 2008 Oct; 31(8):477-84. PubMed ID: 18928745
    [Abstract] [Full Text] [Related]

  • 2. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.
    Gisbert JP, González-Lama Y, Maté J.
    Inflamm Bowel Dis; 2007 May; 13(5):629-38. PubMed ID: 17243140
    [Abstract] [Full Text] [Related]

  • 3. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease.
    de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH.
    Inflamm Bowel Dis; 2005 Nov; 11(11):972-6. PubMed ID: 16239842
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Renal effects of long-term treatment with 5-aminosalicylic acid.
    Patel H, Barr A, Jeejeebhoy KN.
    Can J Gastroenterol; 2009 Mar; 23(3):170-6. PubMed ID: 19319380
    [Abstract] [Full Text] [Related]

  • 6. 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.
    Zallot C, Billioud V, Frimat L, Faure P, Peyrin-Biroulet L, CREGG (Club de Reflexion des cabinets et Groupes d'Hépato-Gastroentérologie).
    J Crohns Colitis; 2013 Aug; 7(7):551-5. PubMed ID: 22999780
    [Abstract] [Full Text] [Related]

  • 7. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
    Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ.
    Aliment Pharmacol Ther; 2001 Aug; 15(8):1131-7. PubMed ID: 11472315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?
    Elseviers MM, D'Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, Capasso G, Van Outryve M, Mishevska-Mukaetova P, Djuranovic S, Pelckmans P, De Broe ME, 5-ASA Study Group.
    Clin Nephrol; 2004 Feb; 61(2):83-9. PubMed ID: 14989626
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U.
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN, Nugent Z, Blanchard JF.
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [Abstract] [Full Text] [Related]

  • 17. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
    Corrigan G, Stevens PE.
    Aliment Pharmacol Ther; 2000 Jan; 14(1):1-6. PubMed ID: 10632639
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.